Chromoblastomycosis in children and adolescents in the endemic area of the Falcón State, Venezuela.
The present paper describes 22 cases of chromoblastomycosis (CBM) caused by Cladophialophora carrionii in children and adolescents (2-19 years old). The patients were seen between 1992 and 2004 and all resided in a CBM endemic area in the semi-arid zone of the Falcón state, Venezuela. Twelve of the 22 patients (54.55%) had close relatives who also had CBM and 19 (86.36%) were male. Lesions consisted of erythematous papules with desquamation or squamous plaques (0.12-14.19 cm in diameter), located primarily on the upper limbs (77.27% of patients). Thirteen of the patients were treated with topical 5-fluorouracil (5-FU; 1% cream), seven with topical ajoene (0.5% gel) and two had electrodesiccation and/or fulguration. Two patients who did not respond to 5-FU were treated with oral itraconazole (100 mg/day for 1 month). Complete clinical and mycological remission was achieved in 17/20 (85%) of the patients treated with 5-FC, ajoene and electrodesiccation and/or fulguration. In addition, similar results were obtained with the two patients who received itraconazole therapy. These cases emphasize the importance of early diagnosis in difficult-to-treat mycotic diseases such as CBM. By early intervention we were able to employ topical treatment with a minimum of adverse effects to achieve a high percentage of favorable therapeutic responses. The patients were thus able to avoid the evolution of the chronic, deforming and incapacitation clinical manifestations associated with CBM.
Pérez-Blanco
M
M
Centro de Investigaciones Biomédicas, Universidad Nacional Experimental Francisco de Miranda, Coro, Estado Falcón, Venezuela. maperez@reacciun.ve
Hernández Valles
R
R
García-Humbría
L
L
Yegres
F
F
D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D001203:Ascomycota / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D002862:Chromoblastomycosis / Q000188:drug therapy* / Q000382:microbiology; D004220:Disulfides / Q000627:therapeutic use; D004564:Electrocoagulation; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D012074:Remission Induction; D013454:Sulfoxides; D016896:Treatment Outcome; D014687:Venezuela
D000935:Antifungal Agents; D004220:Disulfides; D005782:Gels; D007166:Immunosuppressive Agents; D013454:Sulfoxides; D017964:Itraconazole; C048980:ajoene; D005472:Fluorouracil